| Description | It is a human neutralizing antibody, which specifically recognizes ZIKV E glycoprotein. It targets a novel site of vulnerability centered on the Envelope (E) domain I/III linker region and protects mice from viremia and viral dissemination following ZIKV or DENV-2 challenge. This antibody has neutralizing efficiency against ZIKV with IC₅₀ lower than 10 ng/mL. It also has cross reactivity against DENV. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | ZIKV |
| Cross Reactivity | DENV-1, DENV-2, DENV-3, DENV-4 |
| Epitope | AA 299-306 |
| Neutralization Mechanism | It targets a novel site of vulnerability centered on the Envelope (E) domain I/III linker region of ZIKV E. |
| IC50 | 1.0 ng/mL |
| Affinity | KD = 4.8 nM |
| Isotype | IgG |
| Expression Species | HEK293F or CHO cell |
| Purity | >95%, determined by SDS-PAGE and SEC-HPLC |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; BLI; Neut |
| Application Notes | Neutralization assay (Neut): The IC₅₀ value of this antibody against ZIKV and DENV-2 is 1.0 μg/mL and 1.8 μg/mL, respectively. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | ZIKV E |
| Alternative Name | Zika virus envelope glycoprotein; E protein; Env |
| Research Area | Infectious Disease |
| Related Disease | Severe neurological diseases |
Figure 1 The effect of MZ4 antibody to neutralize ZIKE and DENV-2.
The antibody has potent neutralizing ability against ZIKE and DENV-2.
Figure 1 The effect of MZ4 antibody to neutralize ZIKE and DENV-2.
